stern Russia A. Chechulova1; S. Kapustin2; V. Soroka1; V. Soldatenkov2; L. Papayan2; M. GalchenkoPetersburg, Russian Federation; 2Dzhanelidze Analysis Institute of Emergency Medicine, Saint Petersburg, Russian Federation Background: Vitamin K plays a important role in hemostasis by activating each procoagulant (FII, VII, IX, X) and anticoagulant (proteins C, S, Z) things. Vitamin K-epoxide reductase 1 (VKORC1) G-1639A gene polymorphism is identified to affect an enzyme activity and bioavailability of vitamin K. To date, there is a small data on the function of VKORC1 G-1639A variation in venous thromboembolism (VTE) development, in distinct, in patients with inherited thrombophilia. Aims: To assess effect in the VKORC1 G-1639A gene polymorphism on the threat of VTE development in sufferers from North-Western Russia. Techniques: We integrated 600 VTE patients (294 males and 306 females, imply age 43.65.three years) originated from the North-Western region of Russia in the study. The control group (CG) consisted ofDzhanelidze Study Institute of Emergency Medicine, St. Petersburg,Russian Federation; 2Russian Investigation Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation; 3Saint Petersburg State Agrarian University, St. Petersburg, Russian Federation Background: Issue XII (FXII, Hageman factor) is involved in initiation of internal blood coagulation pathway, regulation of fibrinolysis and kallikrein-kinin program. The FXII 46 C/T gene polymorphism is associated with lower of both level and activity of this factor. Role of the FXII 46 C/T polymorphism in venous thromboembolism (VTE) improvement is still not clear.ABSTRACT843 of|Aims: To evaluate the part in the FXII 46 C/T gene polymorphism in VTE development in patients in the North-Western Russia. Techniques: We examined 600 patients (294 males and 306 females, mean age – 43.65.3 years) with VTE. In 400 patients, the initial episode of VTE was diagnosed at young age (45 years or less). Other 200 sufferers IP Agonist custom synthesis composed the group with late-onset VTE. The handle group (CG) consisted of 200 age- and sex-matched healthy persons. All men and women originated from the North-Western Russia and gave informed consent for participation inside the study. Genotyping for the FXII 46 C/T polymorphism was performed by PCR-RFLP. The differences in genotypes DP Agonist list Distribution among the groups were estimated by Fisher`s exact test. Results: Distribution in the FXII 46 C/T variants was comparable involving VTE patients and CG. Frequencies for the CC, CT and TT genotypes have been 48.two , 43.0 , eight.8 in patients, and 48.0 , 45.5 , six.five in controls, respectively. The 46T allele was extra frequently present in patients with late-onset VTE (58.0 vs. 48.eight in young sufferers; OR = 1.5; P = 0.038). Homozygosity for the 46T allele was identified in 24 (12.0 ) patients with late-onset VTE and 29 (7.three ) young sufferers (OR = 1.7; P = 0.066). When in comparison to CG, the frequency of 46TT genotype was practically 2-fold improved in individuals with VTE manifested soon after 45 years old (12.0 vs. 6.5 , respectively; OR = 2.0; P = 0.083). Conclusions: Our information suggest that the FXII 46 C/T gene polymorphism could be a achievable danger element for late-onset VTE development in sufferers from the North-Western Russia.acquired risk components had been infection (28 ), surgery (9 ) and trauma (7 ). No acquired danger components had been identified in 22 (41 ) kids. Seizures (28 ), vomiting (22 ), fever (19 ) and headache (19 ) have been by far the most typical symptoms. Hemiplegia/hemiparesis (35 ),
